Herceptin now available for subcutaneous injection

A subcutaneous formulation of the breast cancer treatment Herceptin (trastuzumab) that significantly reduces administration time is now available.

HER2 status must be established before starting treatment with Herceptin
HER2 status must be established before starting treatment with Herceptin

Herceptin (trastuzumab) 600mg/5ml solution for subcutaneous injection reduces administration time to 2–5 minutes compared with the 30–90 minutes needed for intravenous infusion. In addition, the subcutaneous formulation is given in a fixed treatment regimen of 600mg every three weeks, in contrast to the dose for intravenous administration which must be calculated on the basis of body weight.

Breast cancer use only

The new formulation is licensed for use only in HER2-positive metastatic or early breast cancer. The intravenous preparation can also be used to treat HER2-positive metastatic gastric cancer within its licensed indication.

Non-inferior to iv injection

The open-label, phase 3 HannaH trial was conducted to establish the non-inferiority of subcutaneous injection to intravenous infusion for administration of trastuzumab. A total of 596 patients with HER2-positive operable, locally advanced or inflammatory breast cancer were randomly assigned to undergo eight cycles of neoadjuvant chemotherapy in combination with trastuzumab every three weeks given by either the intravenous or subcutaneous route.

Results showed that subcutaneous trastuzumab was non-inferior to intravenous trastuzumab, with comparable serum trough concentrations (measured at predose cycle 8 before surgery) and pathological complete response rates (45.4% and 40.7%, respectively).

View Herceptin drug record

Further Information: Roche

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...